|Drug, bio-affecting and body treating compositions patents - Monitor Patents|
USPTO Class 424 | Browse by Industry: Previous - Next | All
Recent | 14: | | | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn | | 2008 | 2007 |
Drug, bio-affecting and body treating compositionsBelow are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application. 12/04/2014 > 188 patent applications in 109 patent subcategories.
20140356281 - Dual specific binding proteins directed against il-1 and/or il-17: Engineered multivalent and multispecific binding proteins that bind IL-1β and/or IL-17 are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease.... Agent:
20140356282 - 100mo compounds as accelerator targets for production of 99mtc: Methods of synthesizing 100Mo2C and 99mTcO4− are disclosed. Methods of 100Mo2C generation involve thermally carburizing 100MoO3. Methods of 99mTcO4 generation involve proton bombardment of 100Mo2C in a cyclotron. Yields of 99mTcO4 can be increased by sintering 100Mo2C prior to bombardment. The methods also include recycling of 100Mo2C to form 100MoO3.... Agent: Washington University
20140356283 - Probes, methods of making probes, and methods of use: Embodiments of the present disclosure provide for water soluble polyethylene glycol (PEG)-polymeric melanin (PEG-melanin) nanoparticles, methods of using the PEG-melanin nanoparticle, methods of making the PEG-melanin nanoparticle, methods of imaging a diseases or condition (e.g., pre-cancerous tissue, cancer, or a tumor), and the like. Embodiments of the present disclosure can... Agent:
20140356285 - Compositions and methods related to tissue targeting: Systems and reagents for identification, characterization and/or targeting of particular tissue or cell markers are disclosed. Methods and compositions for in vivo and in vitro targeting of particular targets are also disclosed. Peptides are employed for targeted delivery of therapeutic or imaging agents.... Agent: The Board Of Regents Of The University Of Texas System
20140356284 - Hydrophobic modified peptides for liver specific diagnosis: The present invention relates to hydrophobic modified peptides for the specific delivery of labels to the liver, preferably to hepatocytes, in vitro as well as in vivo. The present invention relates to pharmaceutical compositions comprising said hydrophobic modified peptide(s) and the label(s) to be specifically delivered to the liver. The... Agent:
20140356289 - Multisomes: encapsulated droplet networks: The invention provides a droplet encapsulate comprising: a drop of a hydrophobic medium; a peripheral layer of non-polymeric amphipathic molecules around the surface of the drop; and an aqueous droplet within the peripheral layer, the aqueous droplet comprising: (a) an aqueous medium and (b) an outer layer of non-polymeric amphipathic... Agent:
20140356287 - Plod2 as a target of intervention for sarcoma metastasis: The invention provides compositions and methods for treating a disease or disorder by lowering the level of PLOD2 in a subject.... Agent: The Trustees Of The University Of Pennsylvania
20140356286 - Polypeptides targeting vascular endothelial growth factor receptor-2 and alpha v beta 3 integrin: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.... Agent: The Board Of Trustees Of The Leland Stanford Junior University
20140356288 - Topical examination compositions and methods: Topical compositions for examining the tissue under human breasts for lumps, nodules, knots or thickening comprising: (a) a “Pro Breast Health Complex” consisting essentially of (i) Green Tea Extract, (ii) Vitamin D, or a derivative thereof, (iii) Vitamin E, or a derivative thereof, and (iv) Oenothera Biennis Oil; and (b)... Agent: Melissa Kirkpatrick
20140356291 - Idh1-mutated human glioblastoma cell lines and xenografts: IDH1-mutant cell lines and xenografts (e.g., IDH1R132H heterozygous and IDH1R132H homozygous) are derived from human glioblastoma multiforme (GBM) samples. Methods use said cells and xenografts as tools for determining the impact of IDH1R132H on cancer properties including cellular morphology, tumorigenesis, DNA, apoptosis, and metabolic profiles. Methods also use these cell... Agent: Duke University
20140356290 - Methods for therapeutic renal denervation: Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or... Agent:
20140356293 - Fluorescent compositions with enhanced fluorescence and methods based thereon: Fluorescent compositions with enhanced fluorescent intensity are provided. Methods for using the fluorescent compositions in medical imaging are also provided. The enhanced fluorescent compositions can be a mixture or solution comprising a fluorescent dye and a light-scattering emulsion or fluorescence-enhancing diluent. The fluorescent dye, e.g., indocyanine green (ICG), is activated... Agent: The Research Foundation Of The State Of University Of New York
20140356294 - Dosage that is safeguarded from abuse: The invention relates to a dosage form that is thermoshaped without being extruded and that is safeguarded from abuse, comprising at least one synthetic or natural polymer having a breaking strength of at least 500 N in addition to one or more active substances that could be subject to abuse... Agent: GrÜ Nenthal Gmbh
20140356295 - Cosmetic compositions comprising tobacco seed-derived component: Cosmetic compositions are provided that include an extract from a seed of the Nicotiana species, one or more cosmetically acceptable carriers to act as a diluent, dispersant or carrier for the composition, and optionally one or more cosmetic adjuvants. The tobacco seed extract is typically characterized as having a significant... Agent:
20140356296 - Use of isosorbide derivatives for producing cosmetic preparations: wherein R and R′, independently of one another, are: (i) hydrogen atom, or (ii) radical COR″, wherein R″ is linear or branched, saturated or unsaturated alkyl radical having 5 to 23 carbon atoms, or (iii) linear or branched, saturated or unsaturated alkyl radical having 6 to 22 carbon atoms, or... Agent: Basf Se
20140356297 - Oral compositions for absorption of phosphorous compounds: The present invention provides medicaments useful for reducing phosphorus serum level, especially in those subjects affected from hyperphosphatemia. More specifically, the present invention relates to pharmaceutical compositions to be administered by oral route in fasting periods, in order to absorb phosphorus compounds from fluids of the enteric tract, especially from... Agent:
20140356298 - Mouthwash composition for preventing and/or treating periodontal diseases: The present invention has an object to provide a mouthwash composition for preventing and/or treating periodontal diseases safely and effectively. The present invention solves the above object by providing a mouthwash composition for preventing and/or treating periodontal diseases, characterized in that it comprises, as an effective ingredient(s), one or more... Agent:
20140356299 - Oral care compositions: The invention provides oral care compositions comprising isobutyl magnolol and propylene glycol monolaurate, together with methods of making and using the same. Also described is a method of enhancing the solubility of isobutyl magnolol in an oral care composition comprising effective amount of propylene glycol monolaurate. The composition is for... Agent: Colgate-palmolive Company
20140356300 - Oral care compositions: Disclosed herein are compositions comprising a fluoride ion source, a poly(propylene oxide)/poly(ethylene oxide) copolymer, and optionally a sparingly soluble acid; and methods of using and of making the same.... Agent: Colgate-palmolive Company
20140356301 - Galactolipids-enriched plant extracts and the uses thereof: The present invention is related to a galactolipids-enriched plant extract, prepared by extracting a plant sample selected from a group consisting of: Gynura divaricata subsp. formosana (Asteraceae) (GD), Murdannia bracteata (C. B. Clarke) J. K. Morton ex D. Y. Hong (Commelinaceae) (MB), and Crassocephalum rabens S. Moore (Asteraceae) (CR) with... Agent: Academia Sinica
20140356302 - Buoyant cosmetic gel formulation: A buoyant cosmetic gel formulation with a high moisture content that increases the longevity and facilitates the application of the formulation on a user's skin through various means of application. The buoyant cosmetic gel formulation contains a volatile liquid, a polysaccharide as a film forming and structuring agent, a humectant,... Agent: Spatz Laboratories
20140356304 - Esterified oligomeric polyhydric alcohols for antiperspirant and deodorant applications: Antiperspirant and/or deodorant compositions commonly contain montan wax derivatives that may function as structurants preventing syneresis in cream antiperspirant and deodorant compositions, especially anhydrous cream formulations. Because montan wax derivatives are obtained via natural resources (lignite wax), the quality of the derivatives is often inconsistent and unreliable. There is therefore... Agent: Basf Se
20140356305 - Hair care composition: Hair care composition comprising from about 0.1% to about 20% of a sulfopropyl(meth)acrylate compound, an alpha methylene lactone, or a mixture thereof, wherein the sulfopropyl(meth)acrylate compound and the alpha methylene lactone each have a molecular weight of less than 500 grams/mole; and a dermatologically acceptable carrier.... Agent:
20140356308 - Non-aqueous hair oil composition comprising isoparaffin base oil, silicone elastomer and its solubilizer: Disclosed is a non-aqueous hair care composition comprising: a base oil being a volatile isoparaffin; a silicone elastomer; a solubilizer for the silicone elastomer which is a non-volatile silicone having a viscosity from about 25 to about 100,000 mm2·s−1. The composition of the present invention has improved stability such as... Agent: The Procter & Gamble Company
20140356309 - Use of acid in the manufacture of organopolysiloxane: The present invention relates to a use of an acid in a manufacture of an organopolysiloxane through a condensation reaction of a silicon-containing compound containing a silicon-bonded hydroxyl group and a silicon-containing compound containing a silicon-bonded aminoxy group. Particularly, the present invention relates to a low-odor composition including such an... Agent:
20140356306 - Hair composition with improved rheology: A hair treatment composition comprising a thickener which comprises a copolymer derived from the polymerization of at least a non-ionic monomer (a) and at least a cationic monomer (b).... Agent: Conopco, Inc., D/b/a Unilever
20140356307 - Hair conditioning composition having higher yield point and higher conversion rate of fatty compound to gel matrix: Disclosed is a hair conditioning composition comprising: (a) a cationic surfactant; (b) a high melting point fatty compound; and (c) an aqueous carrier; wherein the cationic surfactant, the high melting point fatty compound, and the aqueous carrier form a gel matrix; wherein the composition has from about 90% to about... Agent:
20140356310 - Cosmetic use of dedifferentiated plant cells: The present invention relates to the cosmetic use of dedifferentiated plant cells of a plant of the Rosa sp. genus, or of an extract or a lyophilisate of said cells, as an active agent for caring for aged skin or aged hair. It also relates to rose dedifferentiated cells, in... Agent: L'oreal
20140356311 - Adhesive agent for application on a sanitary object: Agent for sanitary facilities that can be applied directly on the sanitary object, adheres, and is flushable only after a large number of flushes. The agent comprises fillers from the group of surfactants and a bonding agent, wherein the bonding agent is selected from the group of polyalkylene derivatives, hydrogentated... Agent:
20140356312 - Compositions and their use: Aqueous compositions, methods of manufacturing such aqueous compositions, and methods of removing reducing and/or suppressing malodours using such aqueous compositions are described. These compositions utilize a combination of hydrogen peroxide, a source of copper II, nonionic surfactant and alcohol to provide a highly effective and stable malodour removing, reducing and/or... Agent:
20140356313 - Dermal protector: A dermal protector liquid including a barrier and antimicrobial materials is disclosed. The protector liquid can be sprayed onto the skin. The protector liquid can have a dispersant and moisturizer. When the base and solvents of the liquid evaporate, a polymer barrier and antimicrobial material can continue to reside on... Agent:
20140356314 - 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex: The present invention discloses a 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex, preferably an amorphous 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex formed by the reaction between a cation exchange resin and 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol or a pharmaceutically acceptable acid addition salt thereof. It can exhibit an in-vitro release rate of 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol from the 3-[3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex which is in... Agent:
20140356315 - Triblock copolymer and use therefor: each CNR is independently a polymer segment having a repeating unit containing as part of a pendant group a cyclic nitroxide radical that binds to the polymer main chain via a linking group having at least one imino group or ether bond, and PEG is a segment containing poly(ethylene glycol).... Agent:
20140356316 - Amine polymers for use as bile acid sequestrants: The present invention provides crosslinked amine polymers effective for binding and removing bile salts from the gastrointestinal tract. These bile acid binding polymers or pharmaceutical compositions thereof can be administered to subjects to treat various conditions, including hypercholesteremia, diabetes, pruritus, irritable bowel syndrome-diarrhea (IBS-D), bile acid malabsorption, and the like.... Agent: Relypsa, Inc.
20140356317 - Cold prepared gel and method for making same: A gel comprising water, pectin having a DE from about 62 to 75, soluble saccharide or sugar alcohol solids present in an amount from about 44 to 60% by weight of the gel, and a pH reducing agent for reducing the pH of the gel from a level from about... Agent:
20140356318 - Adoptive cell therapy with specific regulatory lymphocytes: The present invention comprises a method of treatment of an autoimmune disease involving a specific tolerance induction (“STI”) event, wherein the method includes: collecting a first sample from the patient prior to the STI event; detecting an STI event or performing a procedure that correlates in time to an STI... Agent:
20140356323 - Compositions and methods for soft tissue augmentation: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.... Agent:
20140356322 - Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins that are degraded and/or otherwise inhibited by bifunctional compounds of the present invention. In particular, the present invention is directed to compounds, which contain on... Agent:
20140356319 - Compounds and pharmaceutical combinations for the treatment of neurodegenerative and ischemic brain diseases: The present invention describes peptides comprising phycocyanobilin (PCB), as well as the medical use of said peptides and that of PCB, due to the neuroprotector and/or neuroregenerative effects identified for them. Furthermore, pharmaceutical combinations of said peptides and of PCB with proteins or other peptides with synergic effect justify their... Agent: Centro De IngenierÍ A GenÉ Tica Y BiotecnologÍ A
20140356321 - Materials and methods for treatment of liver cancer: Granulin-epithelin precursor (GEP), a pluripotent growth factor, is a hepatic oncofetal protein defining a cancer stem cell (CSC) population in liver cancer. The present invention provides the use of GEP inhibitors (including anti-GEP antibody) for inhibiting immune evasion by liver cancer cells and for eliminating liver cancer stem cells.... Agent: The University Of Hong Kong
20140356320 - Polyoma virus jc peptides and proteins in vaccination and diagnostic applications: The present invention relates to the field of vaccination or immunization, in particular therapeutic vaccination, and diagnosis. Pharmaceutical compositions and kits capable of eliciting a protective immune response against polyoma virus JC (JCV) are disclosed, which may be used e.g., for therapy or for prevention of progressive multifocal leukoencephalopathy (PML)... Agent: Universitä T Zü Rich
20140356324 - Crystal of recombinant interferon with altered spatial configuration, three-dimensional structure and uses thereof: This invention provides crystalline recombinant interferon (rSIFN-co (SEQ ID NO: 1)) having (i) the same amino acid sequence as that of human consensus interferon, and (ii) altered three-dimensional structure as compared to IFN-α2b. The interferon of the present invention exhibits enhanced biological activities. The present invention also provides a structural... Agent:
20140356325 - Novel 2'-c-methyl nucleoside derivative compounds: Compositions and methods relating to 2′-C-methyl nucleoside 5′-monophosphate derivative compounds are provided. In some embodiments, the novel compounds are useful to treat viral infections. In particular, 2′-C-methyl nucleoside 5′-monophosphate derivative compounds, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral infection... Agent: Ligand Pharmaceuticals Incorporated
20140356326 - Biologically active proteins having increased in vivo and/or in vitro stability: The present invention provides unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous... Agent: Amunix Operating Inc.
20140356327 - Gene therapy for spinal cord disorders: The disclosure pertains to methods and compositions for treating disorders affecting the central nervous system (CNS). These disorders include neurometabolic disorders such as lysosomal storage diseases that affect the central nervous system, e.g., Niemann-Pick A disease. They also include disorders such as Alzheimer's disease. The disclosed methods involve contacting an... Agent: Genzyme Corporation
20140356328 - Subfamily e simian adenoviruses a1321, a1325, a1295, a1309, a1316 and a1322 and uses thereof: Recombinant vectors comprise simian adenovirus A1321 (SAdV-A1321), SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus SAdV-A1321, SAdV-A1325, SAdV-A1295, SAdV-A1309, SAdV-A1316, and/or SAdV-A1322 gene(s) is also disclosed. Methods of using the vectors and cell lines... Agent:
20140356329 - Probiotics for use in reducing the incidence and duration of illness: The present invention provides probiotic compositions suitable for reducing the incidence and duration of human illness. In particular, the present invention provides methods and compositions suitable for preventing disease in young children. In some particularly preferred embodiments, the present invention finds use in the prevention respiratory disease in children.... Agent: Dupont Nutrition Biosciences Aps
20140356337 - Composition comprising an activated microbial biomass: The present invention relates to a composition comprising a substrate capable of being evenly coated with a microbial biomass, wherein said biomass represents from 10% to 30% by dry matter of the total dry matter of the coated substrate. It also relates to a method for preparing said composition and... Agent:
20140356338 - Rice-fermented food composition containing rice saccharified liquid fermented with kimchi lactic acid bacteria as active ingredient and having antibacterial and antiviral effects: Disclosed are a rice-fermented food composition which contains a rice saccharified liquid fermented with kimchi lactic acid bacteria as an active ingredient and has antibacterial and antiviral effects. More particularly, the present invention relates to a rice lactic acid bacteria fermented food composition which is prepared by adding kimchi lactic... Agent:
20140356330 - Novel isolated bacteriophage having e. coli-specific bactericidal activity and antibacterial composition comprising the same: The present invention relates to a novel bacteriophage having an E.-coli-specific bactericidal activity, a composition for the prevention or treatment of infectious diseases caused by Enterotoxigenic E.-coli comprising the bacteriophage as an active ingredient, an antibiotic comprising the bacteriophage as an active ingredient, a feed additive composition comprising the bacteriophage... Agent:
20140356332 - Enhancing vessel lesion homing and repair potential of stem cells: Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-β expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-β blocking agent to a subject who has a vascular lesion or is at risk of developing a... Agent:
20140356331 - Injectable cns-derived ecm for tissue reconstruction: Methods useful for preparing central nervous system (CNS) derived extracellular matrix (ECM) materials, including powders and gels are provided. Also provided are CNS ECM preparations prepared according to those methods, and methods of treating a patient or mammal with CNS injury.... Agent: University Of Pittsburgh-of The Commonwealth System Of Higher Education
20140356335 - Mammalian fetal pulmonary cells and therapeutic use of same: A pharmaceutical composition comprising as an active ingredient an isolated population of cell suspension from a mammalian fetal pulmonary tissue is disclosed. The fetal pulmonary tissue is at a developmental stage corresponding to that of a human pulmonary organ/tissue at a gestational stage selected from a range of about 20... Agent:
20140356336 - Method for inducing differentiation enabling tumorigenesis of ips cells to be suppressed: The object of the invention is to provide a technique of suppressing tumorigenesis in IPS cells and inducing differentiation into target differentiated cells. In use of a statin and a differentiation inducer, iPS cells are differentiated into target differentiated cells, whereby iPS cells can be differentiated into differentiated cells in... Agent:
20140356334 - Methods for improved wound closure employing olivamine and endothelial cells: The present disclosure relates to compositions for and methods of improving wound healing, including compositions for and methods of treating chronic wounds, and compositions for the inhibition and treatment of necrosis and extended quiescence that result in cellular necrosis instead of normal proliferation. The methods for wound healing administer one... Agent:
20140356333 - Nail stem cells and methods of use thereof: The present invention is directed to an in vitro method for promoting proliferation, survival, and/or differentiation of K14+, K17+ nail stem cells (NSCs). The instant methods may be used to generate an expanded population of K14+, K17+ NSCs in vitro and expanded NSC populations in which a Wnt pathway is... Agent:
20140356339 - Sequence-based measures of immune response: The invention is directed to methods of measuring an immune response by comparing sequence-based clonotype frequency data from successively measured clonotype profiles. In particular, the invention includes immunotherapies of cancers, such as lymphomas, that include sensitive pre- and post-vaccination sequence-based measurements of changes in a patient's immune repertoire, thereby providing... Agent: Sequenta Inc.
20140356340 - Extensional viscosity to promote safe swallowing of food boluses: Nutritional products having improved cohesiveness of food boluses and methods of making and using same are provided. The nutritional products may include nutritional compositions and high molecular weight, water-soluble polymers such that the nutritional products have extensional viscosities that provide improved cohesiveness to the nutritional products and Trouton ratios of... Agent:
20140356341 - Medication and treatment for disease: A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least... Agent:
20140356342 - Human beta-adrenergic receptor kinase polypeptide and methods: Various embodiments of the invention provide human kinases and phosphatases (KPP) polypeptides and polynucleotides which identify and encode KPP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of KPP.... Agent:
20140356343 - Composition for treating parkinson's disease: A composition useful for the treatment of degenerative brain disease. A pharmaceutical composition comprising an effective amount of apamin as an active ingredient and an effective amount of at least another compound including a permeability enhancer and/or carrier molecule.... Agent:
20140356344 - Mirac proteins: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.... Agent: Bioatla LLC
20140356345 - New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus: The invention relates to a new family of proteolytic enzymes having the ability to hydrolize at a p H between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been... Agent: Fondazione Istituto Insubrico Di Ricerca Per La Vita
20140356346 - Modified coagulation factor viia with extended half-life: The present invention relates to the fields of Factor VII (FVII) and Factor VIIa (FVIIa) albumin linked polypeptides. More specifically, the invention relates to cDNA sequences coding for human Factor VII and Factor VIIa and derivatives genetically fused to a cDNA coding for human serum albumin which may be linked... Agent: Csl Behring Gmbh
20140356347 - Novel serine protease variants: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as... Agent:
20140356348 - Methods of predicting and decreasing the risk of pregnancy loss: Described are methods for diagnosing and predicting the risk of pregnancy loss in a subject based on the presence of an aberrant humoral response to three proteins, Apolipoprotein B-100, alpha2macrogloblin (alpha2M), and fibronectin. The presence or a detectable level of maternal IgG antibodies to trophoblast-derived fibronectin and/or ApoB-100, and/or the... Agent: University Of Louisville Research Foundation, Inc.
20140356349 - Biomarkers of resistance to her2 inhibitors: Provided is a method of suppressing resistance to an anticancer drug, comprising administering an inhibitor of expression or activity of ECM 1 (Extracellular Matrix Protein 1) to a cancer cell or an individual with cancer.... Agent:
20140356352 - Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a CD79b antibody-drug conjugate for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a CD79b antibody-drug conjugate.... Agent: Hoffmann-la Roche Inc.
20140356350 - Combination therapy to prevent dcis formation and progression to breast cancer: A method of treating a ductal carcinoma in situ (DCIS) lesion in a subject in need thereof is disclosed. The method comprises administering to the subject a therapeutically effective amount of a first agent capable of down-regulating activity and/or expression of at least one component participating in a NOTCH pathway,... Agent:
20140356357 - Compounds and methods for treating inflammatory diseases: A monoclonal secretory IgA antibody, which binds to and neutralizes human TNFα. The secretory antibody is useful in treating a variety of inflammatory conditions in humans.... Agent:
20140356359 - Human growth hormone receptor antagonist antibodies and methods of use thereof: The present invention provides antagonizing antibodies that bind to growth hormone receptor (GHR). The invention further relates to therapeutic methods for use of these antibodies to reduce IGF-1 levels and/or for the treatment and/or prevention of diseases associated with excessive IGF-1, including treatment of acromegaly, gigantism, cancer, diabetic nephropathy, arthritis,... Agent:
20140356355 - Il-17 receptor a antigen binding proteins: The present invention relates to IL-17 Receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, polynucleotide sequences encoding said antigen binding proteins, and compositions and methods for diagnosing and treating diseases mediated by IL-17 Receptor A activation by one or more IL-17 ligands. The present invention relates to... Agent:
20140356351 - Methods of treating progressive forms of multiple sclerosis: The present disclosure relates to methods of treating individuals suffering from progressive forms of multiple sclerosis.... Agent: Abbvie Biotherapeutics Inc
20140356360 - Piperazinyl derivatives for the treatment of cancer: The present invention relates to piperazinyl derivatives of formula (I) and the use thereof as a drug, particularly for the treatment of cancer, the pharmaceutical compositions containing said derivatives, and the method for synthesising same.... Agent:
20140356353 - Targeted binding agents against b7-h1: Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed.... Agent:
20140356354 - Therapy for filovirus infection: The present invention addresses a need for improved treatments for filovirus infections.... Agent: Government Of The United States
20140356356 - Use of il-1 beta binding antibodies: The present invention relates to an IL-1β binding antibody or a functional fragment thereof for use in preventing or reducing risk of experiencing a recurrent cardiovascular (CV) event or a cerebrovascular event in a patient that has suffered of a qualifying CV event.... Agent: Novartis Ag
20140356358 - Variant fc-polypeptides with enhanced binding to the neonatal fc receptor: Described herein are variant Fc-fragments that contain an insertion within or adjacent to a loop that bind to the neonatal Fc receptor (FcRn) with higher affinity and/or higher binding activity at pH 5-6 and approximately the same or lower affinity at a physiologic pH as compared to a control Fc-fragment,... Agent:
20140356361 - Repeated administration of non-immunosuppressive antigen specific immunotherapeutics: This invention relates to repeated administration of antigen-specific immunotherapeutics using protocols, or elements thereof, that do not induce immunosuppression. In some embodiments, the protocol has been previously shown not to induce immunosuppression in a subject.... Agent: Selecta Biosciences, Inc.
20140356362 - Targeted/immunomodulatory fusion proteins and methods for making same: The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, to nucleotide sequences encoding the fusion proteins, wherein the chimeric fusion proteins comprises at least one targeting moiety and at least one immunomodulatory moiety that counteracts the immune tolerance... Agent:
20140356363 - Antigen binding proteins that bind pd-1: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and... Agent: Sorrento Therapeutics, Inc.
20140356364 - Anti-b7-h4 antibodies and their uses: The present invention relates to antibodies (including anti-B7-H4 antibodies) and their antigen-binding fragments and to other molecules (including fusion proteins that bind to the cognate antigen/receptor, etc.) that are capable of immunospecifically binding to B7-H4 and the uses of such molecules in the diagnosis and the treatment of cancer and... Agent: Amplimmune, Inc.
20140356366 - Composition for target membrane protein depletion: A method of target membrane protein depletion comprising treating a cell with a dual binding molecule comprising a first binding domain which binds to a driver membrane protein and a second binding domain which binds to a target membrane protein, wherein the cell comprises a cell membrane, and the driver... Agent: Samsung Electronics Co., Ltd.
20140356365 - Prognostic, screening and treatment methods and agents for treatment of metstasis and inflammation using t54 oncofoetal glycoprotein: Methods and agents are disclosed based on the finding that 5T4 interacts with CXCR4 in the cell membrane to form a complex, and that the 5T4 transmembrane region is involved in the promotion of CXCR4 membrane expression and chemotactic response.... Agent: Cancer Research Technology Limited
20140356367 - Monophosphorylated lipid a derivatives: The present invention provides for monophosphorylated lipid A derivatives and carbohydrate derivatives that are useful as agents in the treatment of diseases and conditions, including cancers. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I-IV. In addition, methods for the treatment of cancers are provided.... Agent: Wayne State University
20140356369 - Antibodies to human gdf8: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or... Agent:
20140356368 - Applications of an immune system-released activating agent (israa): The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the ISRAA polypeptide is for... Agent: Arabian Gulf University
20140356373 - Methods and compositions for treating lupus: The invention relates to compositions and methods for treating lupus. The methods typically comprise the step of administrating one or more compounds selected from isoindigo, indigo, indirubin, or derivatives thereof, such as, Meisoindigo and NATURA in an amount sufficient to treat the lupus; preferably by modulating cytokine expression. Preferably the... Agent: Natrogen Therapeutics International, Inc.
20140356371 - Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (pcsk9): The present invention provides methods for reducing various lipoprotein fractions in the serum of patients. The methods of the invention include reducing serum remnant cholesterol, and/or the serum concentration of one or more LDL-C subfractions in a patient. The methods of the present invention comprise selecting a patient who exhibits... Agent: Regeneron Pharmaceuticals, Inc.
20140356372 - Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor: The present invention provides methods for treating, preventing or reducing the severity of allergic reactions. The present invention also provides methods for enhancing the efficacy and/or safety of an allergen-specific immunotherapy (SIT) regimen. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition... Agent: Regeneron Pharmaceuticals, Inc.
20140356370 - Methods for treating autosomal dominant hypercholesterolemia associated with pcsk9 gain-of-function mutations: The present invention provides methods for treating autosomal dominant hypercholesterolemia (ADH). According to certain embodiments, the ADH is caused by or associated with a gain-of-function mutation (GOFm) in a gene encoding PCSK9. The present invention therefore includes methods comprising selecting a patient who carries a GOFm in one or both... Agent: Regeneron Pharmaceuticals, Inc.
20140356374 - Methods for treatment of muscular dystrophy: The present invention relates to methods and agents useful for treating muscular dystrophy. Methods and agents for treating various physiological and pathological features associated with muscular dystrophy are also provided.... Agent: Fibrogen, Inc.
20140356375 - Anti-wall teichoic antibodies and conjugates: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.... Agent: Genentech, Inc.
20140356376 - Anti-wall teichoic antibodies and conjugates: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.... Agent: Genentech, Inc.
20140356379 - Anti-spla2-v antibodies and uses thereof: The present disclosure relates to isolated antibodies against human SPLA2-V and uses thereof.... Agent:
20140356378 - Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.... Agent: Genera Istrazivanja D.o.o
20140356377 - Compounds for use in boosting coagulation: The present invention relates to inhibitors of antithrombin III and the medical use thereof in treating or preventing bleeding. The inhibitors are preferably used in subjects suffering from an acquired or genetic bleeding disorder, such as haemophilia, or in a subjects having a clinical condition characterised by excessive bleeding, such... Agent: Umc Utrecht Holding B.v.
20140356380 - Neutralizing antibodies and methods of use thereof: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods... Agent: Novimmune S.a.
20140356382 - Exosomes for delivery of biotherapeutics: The present invention relates to exosomes, loaded with biotherapeutic protein and/or peptide and methods of producing them and to the use of such exosomes for delivering protein and/or peptide in vivo, in particular the use of such exosomes in methods of therapy.... Agent:
20140356381 - Methods of purifying heterodimeric proteins using immunoglobulin class switching: The present invention describes novel immunoglobulin compositions that co-engage at least two antigens, e.g. a first and second antigen, or, as outlined herein, three or four antigens can be bound, in some of the scaffold formats described herein. First and second antigens of the invention are herein referred to as... Agent: Xencor, Inc.
20140356383 - Administration of an anti-gcc antibody-drug conjugate and a dna damaging agent in the treatment of cancer: The present invention relates to methods for the treatment of gastrointestinal cancers. In particular, the invention provides methods for treatment of a gastrointestinal cancer by administering an immunoconjugate comprising an anti-GCC antibody molecule in combination with a DNA damaging agent.... Agent:
20140356384 - Erythrocyte-binding therapeutics: Peptides that specifically bind erythrocytes are described. These are provided as peptidic ligands having sequences that specifically bind, or as antibodies or fragments thereof that provide specific binding, to erythrocytes. The peptides may be prepared as molecular fusions with therapeutic agents, tolerizing antigens, or targeting peptides. Immunotolerance may be created... Agent:
20140356385 - Enzymatic conjugation of antibodies: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.... Agent:
20140356386 - Immunization protocol for directed expansion and maturation: A first antigen is administered to a subject to select progenitor B cells that are suitable for subsequent production of a desirable affinity-matured antibody, and then a second antigen is administered to stimulate the expansion of B cells that produce that affinity-matured antibody. An immunization protocol is used in which... Agent: Novartis Ag
20140356387 - Method for inducing immune tolerance through targetted gene expression: A method of inducing immune tolerance against a protein of interest comprising the steps of (a) transducing hematopoietic stem cells with a gene for the protein of interest wherein the gene is operably connected to a platelet specific promoter, and (b) transplanting the transfected cells of step (a) into to... Agent:
20140356388 - Vaccine - screening method: The present invention provides screening methods which may be regarded as in vitro or ex vivo methods of interrogating the immune system to understand what viral antigens are “seen” and responded to by T cells of the immune systems during viral infection. The screening methods further link in vitro or... Agent:
20140356390 - Modulation of replicative fitness by deoptimization of synonymous codons: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic... Agent: The Government Of The United States Of America As Represented By The Secretary Of The Department Of
20140356389 - Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli: Disclosed herein are various open reading frames from a strain of E. coli responsible for neonatal meningitis (MNEC), and a subset of these that is of particular interest for preparing compositions for immunising against MNEC infections.... Agent: Novartis Vaccines And Diagnostics Srl
20140356391 - Amino acid sequences for clinical remission of psoriasis and related diseases.: Polypeptides comprising amino acid sequences of particulate antigens isolated from various species of Leishmania protozoa, or immunogenic variants thereof, are disclosed for the treatment and clinical remission of cutaneous leishmaniasis, psoriasis, psoriatic arthritis, rheumatoid arthritis, atopic dermatitis, seborrheic dermatitis and skin papilloma. Also disclosed are nucleic acid sequences encoding such... Agent:
20140356392 - Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc: Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions... Agent: Taiga Biotechnologies, Inc.
20140356393 - Composition for treatment or prevention of hyperlipidemia, containing water extracts of laetiporus sulphureus: The present invention relates to a composition for the treatment or prevention of hyperlipidemia, the composition containing water extracts of Laetiporus sulphureus as an active ingredient, and to a medicine and a dietary supplement, containing the extracts.... Agent:
20140356394 - Composition for treatment or prevention of obesity, containing water extracts of fomitella fraxinea: The present invention relates to a composition for the treatment or prevention of obesity, the composition containing water extracts of Fomitella fraxinea as an active ingredient, and to a medicine and a dietary supplement, containing the extracts.... Agent:
20140356395 - Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance: This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided.... Agent:
20140356396 - Rotavirus preparations with excess calcium ions and high viscosities that ensure viability at elevated temperatures: The invention describes a set of formulations and methods that provide for stabilization of viruses in liquid and dried states. In particular, formulations include Rotavirus preparations with excess Ca2+ and high viscosities that ensure infective potency at elevated temperatures. Methods include bulk purification of Rotavirus from cell culture and administration... Agent:
20140356397 - Immunogenic treatment of cancer: The present invention provides an immunomodulator for use in the treatment and/or control of a neoplastic disease in a patient intended to undergo immunogenic cell death therapy simultaneously, separately or sequentially with administration of the immunomodulator. The therapy can be selected from microwave irradiation, targeted radiotherapy, embolization, cryotherapy, ultrasound, high... Agent: Immodulon Therapeutics Limited
20140356398 - Adoptive transfer of cd8+ t cell clones derived from central memory cells: The present invention provides a method of carrying out adoptive immunotherapy in a primate subject in need thereof by administering the subject a cytotoxic T lymphocytes (CTL) preparation in a treatment-effective amount. The method comprises administering as the CTL preparation a preparation consisting essentially of an in vitro expanded primate... Agent:
20140356399 - Compositions and methods for treating viral infections: The present disclosure provides compositions and methods useful for treating viral infections. As described herein, the compositions and methods are based on the development of immunogenic compositions that include an inactivated virus in combination with a non-ionic surfactant vesicle (NISV). In certain embodiments at least a portion of the antigen... Agent: Variation Biotechnologies, Inc.
20140356402 - Colour changing composition: A changing colour composition for caring for and/or making up keratin materials is disclosed. The composition comprises in a physiologically acceptable medium, at least: a) microcapsules containing releasable colorant(s), said microcapsules comprising: a core comprising one organic material, at least one layered coating surrounding said core, the layered coating comprising... Agent: L'oreal
20140356403 - Colour changing composition in gel form: A changing colour composition in the form of a gel for caring for and/or making up keratin materials is disclosed. The composition comprises in a physiologically acceptable medium, a) from 0.1 to 10% by weight preferably from 0.5 to 10% more preferably from 1 to 5% by weight relative to... Agent: L'oreal
20140356401 - Liquid cosmetic: A liquid cosmetic which minimizes stickiness or stiffness caused by the incorporation of a large amount of a moisturizing agent is provided. This liquid cosmetic contains 10 to 40% by mass of a moisturizing agent (a), 0.01 to 3% by mass of an oil (b), 0.01 to 5% by mass... Agent: Shiseido Company, Ltd.
20140356400 - Simple micro-particulate suspension of behentrimonium chloride with favorable distributive and adsorptive properties: A personal care composition for hair and skin applications includes an aqueous solution consisting essentially of aggregates of behentrimonium chloride and dihydroxypropyl PEG-5 linoleammonium chloride. The composition forms micro particles or aggregates of behentrimonium chloride that exhibits surprising distributive properties in aqueous solution of a nature beneficial to its application... Agent: Formula Xo, Inc.
20140356404 - Active-powder biocidal composition comprising at least one copper salt and at least one zinc salt and the method for the production thereof: Active-powder biocidal composition comprising at least one copper salt and at least one zinc salt such that the molar ratio between the copper salt and the zinc salt is within the range of 10 to 1 and each copper and zinc salt, separately, has a solubility constant (Kps) within the... Agent:
20140356405 - Antimicrobial constructs: The invention is based on the recognition that known antimicrobial compounds, such as nisin or other lantibiotics, can be made to form a long lasting antimicrobial surface coating by linking the peptide with a block polymer, such as PLURONIC® F108 or an end group activated polymer (EGAP) in a manner... Agent: The State Of Oregon Acting By And Through The State Board Of Higher Ed.on Behalf Of Oregon State
20140356406 - Antimicrobial articles and methods of making and using same: Described herein are glass or glass-ceramic articles having improved antimicrobial efficacy. Further described are methods of making and using the improved articles. The improved articles generally include a glass or glass-ceramic substrate, a compressive stress layer that extends inward from a surface of the glass or glass-ceramic substrate to a... Agent: Corning Incorporated
20140356407 - Biodegradable supporting device: A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of the biodegradable metal scaffold, wherein the biodegradable polymer coating has a degradation rate that is faster than the degradation rate of... Agent:
20140356409 - Cationic peptides and use of such peptides for inhibiting exotoxin production: Cationic peptides and use of such peptides to inhibit bacterial exotoxin production without substantially inhibiting bacterial growth are described.... Agent:
20140356408 - Polymeric compositions containing ambient-temperature stable biopharmaceuticals & methods for formulation thereof: Biopharmaceuticals, such as vaccine agents and probiotics, are encapsulated in carbohydrate-glass particles and embedded in an amorphous polymer substrate to produce polymeric compositions containing ambient-temperature stable biopharmaceuticals for syringeless administration to patients such as via dissolvable films, micro-needle patches and similar medical delivery devices. The amorphous polymer substrate is soluble... Agent:
20140356410 - Biodegradable and biocompatible nano composite t-plate implant and a method of synthesizing the same: The embodiments herein provide a biodegradable and biocompatible T-plate nano-composite implant with stem cells for treating and repairing broken bones, damaged tissues and torn ligaments. The implant comprises a polymeric matrix part comprising poly lactic glycolic acids (PLGA), a bioceramic part comprising hydroxyapatite (HAp) nanoparticles and an endometrial stem cell.... Agent:
20140356411 - Plasmonic-magnetic bifunctional nanotubes for biological applications: The present invention includes nanotubes or rods, methods and arrays using plasmonic-magnetic bifunctional nanotubes or rods comprising: one or more silica nanotubes or rods; one or more nanomagnets embedded in a portion of the silica nanotubes or rods; and plasmonic metal nanoparticles uniformly coating in or on at least a... Agent:
20140356412 - Non-aqueous patch: e
20140356415 - Compositions and vaccines comprising vesicles and methods of using the same: The disclosure relates to compositions, pharmaceutical compositions, vaccines, and methods of making and using the same. The compositions of the disclosure are useful to stimulate an antigen-specific immune response and, in some embodiments, a protective immune response in an animal after challenge to pathogens. The compositions of the disclosure are... Agent: University Of Maryland, Baltimore
20140356418 - Compositions for binding to amyloid proteins: Compositions useful for the prevention and/or treatment of Alzheimer's disease are disclosed. The composition comprises carrier particles each linked to a plurality of peptide constructs comprising a peptide binding sequence capable of binding to an amyloid protein and a transit amino acid sequence linked to said binding sequence. The binding... Agent:
20140356416 - Liposomal drug encapsulation: Provided herein are novel methods of making liposomally encapsulated drugs using reverse pH gradients and optimizing internal buffer compositions. Further provided herein are liposome compositions including an active pharmaceutical ingredient and uses thereof to treat a variety of diseases (e.g. cancer, inflammatory, neurological and cardiovascular diseases).... Agent:
20140356417 - Modified drugs for use in liposomal nanoparticles: Drag derivatives are provided herein which are suitable for loading into liposomal nanoparticle carriers. In some preferred aspects, the derivatives comprise a poorly water-soluble drag derivatized with a weak-base moiety that facilitates active loading of the drag through a LN transmembrane pH or ion gradient into the aqueous interior of... Agent:
20140356419 - Polyherbal composition for skin care: Described herein is a polyherbal composition effective in skin care, including singularly or in certain combinations 0.01% to 15% of Ziziphus extract, 0.01% to 10% of Prunus extract, suitable delivery system, and a suitable carrier.... Agent: Shiromani Gurudwara Prabandhak Committee's Guru Nanak Khalsa College
20140356413 - Retinoid-liposomes for treating fibrosis: What is described are pharmaceutical compositions comprising a double-stranded nucleic acid molecule comprising a sense strand and an antisense strand wherein the sense and antisense strands are selected from the oligonucleotides described as SERPINH1_2 (SEQ ID NOS: 60 and 127), SERPINH1_45a (SEQ ID NOS: 98 and 165), and SERPINH1_51 (SEQ... Agent:
20140356414 - Targeted crosslinked multilamellar liposomes: A liposome composition that is useful for treating a subject in need of cancer treatment includes a cross-linked multilamellar liposome having an exterior surface and an interior surface. The interior surface defines a central liposomal cavity. The multilamellar liposome includes at least a first lipid bilayer and a second lipid... Agent: University Of Southern California
20140356421 - Antibody-conjugated double-emulsion nanocapsule and preparation methods thereof: An antibody-conjugated double-emulsion nanocapsule is provided. A linking group is introduced on the surface of a double-emulsion nanocapsule, which is composed of an oily shell enclosing an aqueous core, to link the double-emulsion nanocapsule with an antibody.... Agent: National Chiao Tung University
20140356420 - Micro-particle comprising a protein extract from sweet potato for extending satiety and controlling blood glucose and lipid levels: The present invention relates to a micro-particle for extending satiety and controlling blood glucose and lipid levels, comprising a core having the protein extract from sweet potato, an active ingredient layer coated on the core, and a protection layer coated over the active ingredient layer as an external layer, wherein... Agent:
20140356422 - Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof: The present invention relates to a pharmaceutical formulation for oral administration for preventing or treating allergic rhinitis or asthma, which comprises: (a) a first particle part comprising levocetirizine or a pharmaceutically acceptable salt thereof and an organic acid; and (b) a second particle part comprising montelukast or a pharmaceutically acceptable... Agent: Hanmi Pharm. Co., Ltd.
20140356424 - Composition for treatment or reduction of symptoms related to premenstrual syndrome (pms), premenstrual disphoric disorder (pmdd), premenopause, menopause or female hormonal disorders, in a pharmaceutical composition containing said form, and process for: The present invention relates to the field of food and medicines for the treatment or alleviation of premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), premenopause, menopause and female hormonal disorders. A first embodiment relates to a composition containing vitamins, minerals and oils. Additionally, the invention comprises a pharmaceutical form, more... Agent:
20140356423 - Formulations of lycopene in combination with bisphosphonates bone resorption inhibitors: The present invention provides a pharmaceutical formulation suitable for filling softgel capsules comprising: (a) from about 1% to about 90% by weight of a bisphosphonic acid or a pharmaceutically acceptable salt; (b) from 1% to about 99% by weight of lycopene and (c) from about 40% to about 80% by... Agent:
20140356425 - Composition and method for treating neurological disease: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.... Agent:
20140356426 - Tamper-resistant dosage form containing one or more particles: s
20140356427 - Orally disintegrating tablet containing hydroxyalkyl cellulose microparticles: An orally disintegrating tablet is obtained by dry tabletting a mixture of: hydroxyalkyl cellulose microparticles having a 50% particle size in the cumulative particle size distribution of more than or equal to 15 μm and less than 40 μm, and having a hydroxyalkyl group content of 40 to 80% by... Agent:
20140356428 - Tamper resistant dosage form with bimodal release profile:
20140356431 - Oral administrable pharmaceutical composition:
20140356430 - Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use: Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.... Agent: Signal Pharmaceuticals, LLC
20140356429 - Tablet containing ferric citrate: The present invention provides a new preparation which is a tablet containing (1) ferric citrate, (2) a polyvinyl alcohol-polyethylene glycol graft copolymer, and (3) a polyvinyl alcohol-acrylic acid-methyl methacrylate copolymer... Agent: Japan Tobacco Inc.
20140356432 - Modalities for the treatment of degenerative diseases of the retina: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.... Agent: Advanced Cell Technology, Inc.
20140356437 - Corticosteroids for the treatment of joint pain: Corticosteroid microparticle formulations are provided for use for treating pain, including pain caused by inflammatory diseases such as osteoarthritis or rheumatoid arthritis, and for slowing, arresting or reversing structural damage to tissues caused by an inflammatory disease, for example damage to articular and/or peri-articular tissues caused by osteoarthritis or rheumatoid... Agent:
20140356436 - Dermocosmetic compositions based on a synergistic combination of colloidal silver and deoxyribonucleic acid: The present invention relates to dermocosmetic compositions containing, as active ingredients, a synergistic combination of colloidal silver and deoxyribonucleic acid, characterized in that the colloidal silver is more particularly an aqueous solution of electro colloidal silver.... Agent: Argentum Holding Sà Rl
20140356435 - Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.... Agent: Therakine Biodelivery Gmbh
20140356438 - Peripherally administered viscous formulations: Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10... Agent: Allergan, Inc.
20140356433 - Pharmaceutical carrier and drug structure using the same: The present invention provides a pharmaceutical carrier and a drug structure using the carrier. The drug of the present invention comprises particular contents of chitosan, a negatively charged polymer, sodium tripolyphosphate, and an active ingredient, which combine with each other via electrostatic attraction. The drug structure has better release property... Agent:
20140356434 - Pharmaceutical formulation: Disclosed are aqueous pharmaceutical compositions which provide sustained released delivery of corticosteroid compounds. The pharmaceutical composition comprises an insoluble corticosteroid; a soluble corticosteroid; and at least one viscosity enhancing agent. Also provided are methods for using the pharmaceutical compositions in an epidural injection, intra-articular injection, intra-lesional injection, or an intra-ocular... Agent: Semnur Pharmaceuticals, Inc.
20140356439 - Lipidated glycoprotein particles and methods of use: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.... Agent:
20140356440 - Enteric coated multiparticulate controlled release peppermint oil composition and related methods: A multiparticulate composition is formed from a plurality of individual cores including a hydrophobic phase containing peppermint oil dispersed in a microcrystalline cellulose-based gel and a hydrophilic phase containing a hydrogel. An enteric coating is over the individual cores. The multiparticulate composition can be used to treat gastrointestinal disorders.... Agent: Zx Pharma, LLC
20140356441 - Core-shell type particles and method for producing the same: m
20140356443 - Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions... Agent: Xspray Microparticles Ab
20140356442 - Pharmaceutical compositions of triptorelin microspheres: Sustained release triptorelin microspheres include triptorelin or a salt of triptorelin, a copolymer of lactide and glycolide, and glucose or mannitol. The sustained release triptorelin microspheres have a relatively high initial release after administration, which allows the drug to produce its pharmaceutical effects immediately and to maintain long-term steady pharmaceutical... Agent: Shangdong Luye Pharmaceutical Co., Ltd.
20140356445 - Artificial cell constructs for cellular manipulation: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive... Agent:
20140356444 - Drug loaded polymeric nanoparticles and methods of making and using same: The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol.... Agent: Bind Therapeutics, Inc.
20140356446 - Apparatus and method for separating and concentrating fluids containing multiple components: An apparatus may allow separating and collecting a fraction of a sample. The apparatus, when used with a centrifuge, allows for the creation of at least three fractions in the apparatus. It also provides for a new method of extracting the buffy coat phase from a whole blood sample and... Agent:
20140356447 - Solvent-free process for obtaining phospholipids and neutral enriched krill oils: Organic solvent-free processes for obtaining krill oil compositions are disclosed. The processes include a) cooking krill in a cooker vessel for a time and temperature sufficient to denature the protein content of the krill and cause a first solid krill fraction and first liquid krill fraction to be formed while... Agent:
20140356448 - Treating prostate, ovarian, or breast cancer with a whole, leech saliva extract: Methods are provided for isolating and using a whole-saliva leech extract. The methods can include feeding a phagostimulatory agent to a leech; inducing a regurgitation in the leech, the inducing including placing the leech in an environment having a temperature of less than about 0° C.; and, collecting an unrefined,... Agent: Biopep Solutions, Inc.
20140356449 - Sore throat remedy: A method for treating a sore throat involves administering to a human subject in need of treatment of at least one of cartilage and a material derived from cartilage in a vehicle or composition that promotes or facilitates prolonged or extended contact of a sore throat with at least one... Agent:
20140356450 - Agent for activating sirtuin gene containing egg shell membrane ingredient and composition using the same: Providing an agent for activating a sirtuin gene and an application thereof. The agent for activating a sirtuin gene is characterized to contain an egg shell membrane ingredient, for example an egg shell membrane-containing powder or soluble egg shell membrane ingredient.... Agent: The University Of Tokyo
20140356451 - Polymer chelator conjugates: Provided herein are biocompatible polymer conjugates comprising a biologically compatible polymer covalently bound to a biologically compatible chelator moiety, which in turn are optionally bound, reversibly, to pharmacologically active metal ions. The biologically compatible polymer may comprise of modified placental tissue grafts composed of at least one membrane, capable of... Agent: Mimedx Group, Inc,
20140356452 - Therapeutic uses of tetrachlorodecaoxygen (tcdo): The present invention is based in part on the regulation of macrophages. Additionally, the present invention provides methods for the treatment of various diseases and disorders using a compound which regulates macrophage function.... Agent:
20140356454 - Antibacterial wound dressing: An antibacterial wound dressing is based on or derived from gel-forming fibres such as carboxymethyl cellulose or alginate fibres having silver ions linked thereto at some but not all of the exchangeable sites such that the distribution of silver ions over the exchangeable sites is substantially uniform. The silvered fibres... Agent:
20140356453 - Ion enhancement: wherein R and R1 each independently comprises an alkyl group, and wherein X and Y are independently selected from the group consisting of bromine, chlorine and hydrogen and a second housing having a water accessible compartment containing an insoluble metal ion donor for releasing metal ions when contacted by the... Agent:
20140356459 - Micrornas and uses thereof: The invention relates to molecular targets and their use to counteract tumors. Naturally occurring microRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments... Agent:
20140356457 - Novel means and methods for the treatment of hearing loss and phantom hearing: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with... Agent: University Of Geneva
20140356455 - Pluripotent cell lines and methods of use thereof: Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.... Agent: Parkinson's Institute
20140356456 - Treating cancer with atr inhibitors: This invention relates to methods and compositions for treating pancreatic cancer. More specifically, this invention relates to treating pancreatic cancer with certain ATR inhibitors in combination with gemcitabine and/or radiation therapy. This invention also relates to methods and compositions for treating non-small cell lung cancer. More specifically, this invention relates... Agent:
20140356458 - Treatment of sickle cell disease: The present invention includes embodiments for treatment and/or prevention of sickle cell disease that employ Hydroxyfasudil or Isocoronarin D alone or either in conjunction with each other or an inducer of HbF production. The compounds may act synergistically, and the compounds employed circumvent the side effects seen with Hydroxyurea.... Agent: King Abdullah University Of Science And Technology
20140356460 - Use of hypertonic saline to draw fluid out of swollen tissue and relieve nasal congestion: The optimum concentration of salt in solutions to combat congestion of the mucosa is a relatively narrow range. This use of in hypertonic saline solutions for treatment of congestion of the mucosa having a concentration within the range of 2.3% to and including 2.7% w/v sodium chloride/water with the most... Agent:
20140356461 - Plant disease controlling agent and method for controlling plant diseases using same: Provided is a plant disease controlling agent including magnesium oxide obtained by baking magnesium hydroxide at 400 to 1000° C. Further, provided is a method for controlling plant diseases using the plant disease controlling agent. The method is preferably any of mixing the plant disease controlling agent with the surface... Agent: Ube Material Industries, Ltd.
20140356462 - Muscle atrophy inhibitor: An extract of Citrus depressa, preferably an organic solvent extract of a fruit and/or leaf of Citrus depressa, a supercritical extract of a fruit and/or leaf of Citrus depressa, or a subcritical extract of a fruit and/or leaf of Citrus depressa, containing 0.3 mass % or more of a polymethoxyflavonoid... Agent:
20140356463 - Process for obtaining citrus fiber from citrus peel: A process is disclosed for obtaining citrus fiber from citrus peel. Citrus fiber is obtained having a c* close packing concentration value of less than 3.8 wt % anhydrous base. The citrus fiber can be used in food products, feed products, beverages, personal care products, pharmaceutical products or detergent products.... Agent: Cargill, Incorporated
20140356464 - Organic emulsion comprising dha and epa: The present invention relates to an emulsion of an oil composition comprising docasoahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which is characterised in that the emulsion is essentially free from ascorbyl palmitate.... Agent:
20140356465 - Method of treatment using a therapeutic agent for intranasal administration: A method of intranasal treatment of nasal symptoms administered to a human in need of the treatment includes administering intranasally from an internasal spray container a composition having a therapeutically effective amount of capsicum extract to a human in need thereof; and effecting relief from at least one symptom. The... Agent: Hi-tech Pharmacal Co., Inc.
20140356468 - Composition containing paper mulberry extracts: Disclosed is a use of a composition containing a paper mulberry extract, and more particularly to a use of a composition containing, as an active ingredient, a paper mulberry extract in enhancement of skin moisturization, inhibition of skin aging, alleviation of inflammation, antibacterial activity, pore size reduction, sebum control, skin... Agent: Pacific Corporation
20140356466 - Method for treating pain and inflammation associated with arthritis using chromium-three cation in combination with phyllanthus emblica and shilajit: Chromium-three cation in combination with Phyllanthus emblica extract and Shilajit is useful in treating symptoms associated with osteoarthritis including reduction of inflammation and pain in a mammal, particularly a human or an animal. The combination shows significant reduction in overall pain levels and other pain measures in a canine model,... Agent: Natreon, Inc.
20140356467 - Topical skin care formulations comprising jaboticaba and cashew fruit pulps and extracts thereof: Disclosed are compositions and corresponding methods of their use that include jaboticaba fruit pulp and/or cashew fruit pulp or extracts thereof.... Agent: Mary Kay Inc.Previous industry: Chemistry of inorganic compounds
Next industry: Plastic article or earthenware shaping or treating: apparatus
RSS FEED for 20141204:
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.
Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.
Results in 0.93913 seconds